Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
17 5월 2023 - 8:00PM
Business Wire
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI) (“Spectrum” or
the “Company”), a biopharmaceutical Company focused on novel and
targeted oncology announced today that on May 16, 2023, the Company
received a written notification from the Listing Qualifications
Staff (the “Staff”) of the Nasdaq Stock Market LLC (Nasdaq) that
the Company has regained compliance with the minimum bid price
requirement set forth in Nasdaq Listing Rule 5550(a)(2).
The Company previously received notification from the Staff on
November 1, 2022, that its common stock failed to maintain a
minimum bid price of $1.00 or more over the previous 30 consecutive
business days, as required by the Nasdaq Listing Rules. Since then,
the Staff has determined that for the 10 consecutive business days
from May 2 to May 15, 2023, the closing bid price of Spectrum’s
common stock has been at $1.00 per share or greater. Accordingly,
the Company has regained compliance with Listing Rule 5550(a)(2)
and this matter is now closed.
About Spectrum Pharmaceuticals, Inc.
Spectrum is a commercial stage biopharmaceutical company, with a
strategy of acquiring, developing, and commercializing novel and
targeted oncology therapies. We have an in-house clinical
development organization with regulatory and data management
capabilities, in addition to commercial infrastructure and a field
based sales force for our marketed product, ROLVEDON™
(eflapegrastim-xnst) Injection. For additional information on
Spectrum please visit www.sppirx.com.
Notice Regarding Forward-looking statements
This press release may contain forward-looking statements
regarding future events and the future performance of Spectrum
Pharmaceuticals that involve risks and uncertainties that could
cause actual results to differ materially. These statements are
based on management's current beliefs and expectations. Risks that
could cause actual results to differ include the possibility that
Spectrum’s existing and new drug candidates may not prove safe or
effective, the possibility that our existing and new applications
to the FDA and other regulatory agencies may not receive approval
in a timely manner or at all, the possibility that our existing and
new drug candidates, if approved, may not be more effective, safer
or more cost efficient than competing drugs, the possibility that
our efforts to acquire or in-license and develop additional drug
candidates may fail, the possibility that our commercialization
efforts may not be successful, our dependence on third parties for
manufacturing, distribution and quality control and other risks
that are described in further detail in the company's reports filed
with the Securities and Exchange Commission. The company does not
plan to update any such forward-looking statements and expressly
disclaims any duty to update the information contained in this
press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of
Spectrum Pharmaceuticals, Inc. and its affiliates. REDEFINING
CANCER CARE™ and ROLVEDON™ are the Spectrum Pharmaceuticals’ logos
and trademarks owned by Spectrum Pharmaceuticals, Inc. Any other
trademarks are the property of their respective owners.
© 2023 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230517005282/en/
Nora Brennan Chief Financial Officer 949.788.6700
InvestorRelations@sppirx.com
Lisa Wilson In-Site Communications, Inc. 212.452.2793
lwilson@insitecony.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024